Top

Published in:

01-10-2011 | Short Report

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent

Authors: Steffen Hess, Toni Hospach, Robert Nossal, Günther Dannecker, Klaus Magdorf, Frank Uhlemann

Published in: European Journal of Pediatrics | Issue 10/2011

Abstract

Life-threatening disseminated tuberculosis developed in a 17-year-old girl who was treated with the TNF-α blocker adalimumab for refractory SAPHO syndrome. The patient presented to the emergency department with dyspnea and somnolence and within 2 h developed the clinical picture of a septic shock. In addition to this unusual presentation, she showed a complicated course with increasing cerebral granuloma formation in spite of adequate antimycobacterial treatment. Immune reconstitution after discontinuation of TNF blockade may contribute to this “paradoxical reaction.” Possible implications for screening, diagnosis, and treatment of tuberculosis in children and adolescents receiving anti-TNF treatment are discussed.

Alffenaar JWC, van Altena R, Bökkerink HJ et al (2009) Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 49:1080–1082PubMedCrossRef

Arend SM, Leyten AMS, Franken WPJ et al (2007) A patient with de novo tuberculosis during anti-tumor necrosis factor-α therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 45:1470–1475PubMedCrossRef

Ben Abdelghani K, Dran DG, Gottenberg JE et al (2010) Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 37:1699–1704PubMedCrossRef

Blackmore TK, Manning L, Taylor WJ et al (2008) Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 47:e83–e85PubMedCrossRef

Buonsenso D, Serranti D, Valentini P (2010) Management of central nervous system tuberculosis in children: light and shade. Eur Rev Med Pharmacol Sci 14:845–853PubMed

Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43:717–722PubMedCrossRef

Breen R, Smith C, Bettinson H et al (2004) Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59:704–707PubMedCrossRef

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772PubMedCrossRef

Cooray DV, Moran R, Khanna D et al (2008) Screening, re-screening and treatment of PPD positivity in patients on anti-TNFa therapy (abstract). Arthritis Rheum 58:S546–S547

10.

Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60PubMedCrossRef

11.

Eleftheriou D, Gerschman T, Sebire N et al (2010) Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology 49:1505–1512PubMedCrossRef

12.

Endean AL, Barry SM, Young-Min SA (2009) Possible miliary tuberculosis during adalimumab therapy with negative γ-IFN release assays. Rheumatology 48:319–320PubMedCrossRef

13.

Garcia-Vidal C, Rodriguez-Fernández S, Martínez-Lacasa J et al (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40:756–759PubMedCrossRef

14.

George S, Papa L, Sheils L et al (1996) Septic shock due to disseminated tuberculosis. Clin Infect Dis 22:188–189PubMedCrossRef

15.

Jacob JT, Mehta AK, Leonard MK (2009) Acute forms of tuberculosis in adults. Am J Med 122:12–17PubMedCrossRef

16.

Kampmann B, Whittaker E, Williams A et al (2009) Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J 33:1374–1382PubMedCrossRef

17.

Magdorf K, Detjen AK (2008) Proposed management of childhood tuberculosis in low-incidence countries. Eur J Pediatr 167:927–938PubMedCrossRef

18.

Magrey M, Khan MA (2009) New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Curr Rheumatol Rep 11:329–333PubMedCrossRef

19.

Malipeddi AS, Rajendran R, Kallarackal G (2007) Disseminated tuberculosis after anti-TNFα treatment. Lancet 369:162PubMedCrossRef

20.

Meintjes G, Wilkinson RJ, Morroni C et al (2010) Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24:2381–2390PubMed

21.

Michel P, Barbier C, Loubière Y et al (2002) Three cases of septic shock due to tuberculosis without HIV pathology. Intensive Care Med 28:1827–1828PubMedCrossRef

22.

Moreno C, Taverne J, Mehlert A et al (1989) Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumor necrosis factor from human and murine macrophages. Clin Exp Immunol 76:240–245PubMed

23.

Piana F, Codecasa LR, Cavallerio P et al (2006) Use of a t-cell based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 28:31–34PubMedCrossRef

24.

Schoeman JF, Fieggen G, Seller N et al (2006) Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol 21:301–308PubMedCrossRef

25.

Schoeman JF, Springer P, van Rensburg AJ et al (2004) Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 19:250–257PubMedCrossRef

26.

Shenoi S, Wallace CA (2010) Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 12:367–377PubMedCrossRef

27.

Solovic I, Sester M, Gomez-Reino JJ et al (2010) The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185–1206PubMedCrossRef

28.

Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy. Arthritis Rheum 60:1884–1894PubMedCrossRef

29.

Wallis RS (2009) Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 22:403–409PubMedCrossRef

30.

Wallis RS (2008) Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 58:947–952PubMedCrossRef

31.

Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8:601–611PubMedCrossRef

32.

Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with TNF antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRef

33.

Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39:1254–1256PubMedCrossRef

34.

Wallis RS, van Vuuren C, Potgieter S (2009) Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48:1429–1432PubMedCrossRef

35.

Yoo WH (2010) Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy. Rheumatol Int. doi:10.1007/s00296-009-1357-x

Title: Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent
Authors: Steffen Hess
Toni Hospach
Robert Nossal
Günther Dannecker
Klaus Magdorf
Frank Uhlemann
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: European Journal of Pediatrics / Issue 10/2011
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-011-1501-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2011

Gray hair and acrodermatitis enteropathica-like dermatitis: an unexpected presentation of cystic fibrosis

Management of ligneous conjunctivitis in a child with plasminogen deficiency

Reply to the correspondence letter by Dr. Mitra S. to “alendronate for the treatment of hypercalcaemia due to neonatal subcutaneous fat necrosis”

Can intravenous colistin effectively treat ventilator-associated pneumonia in the pediatric and neonatal patients?

The side effects of phototherapy for neonatal jaundice: what do we know? What should we do?

Haemodynamically unstable preterm infant: an unresolved management conundrum